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ABSTRACT 
Use of new amphetamine-type stimulants (ATS) as designer drugs is a serious problem worldwide. ATS are used in 
tablet, capsule, and powder forms, and can be mixed with other drugs. There is little information available on how these 
new drugs are metabolized or their ability to inhibit the metabolism of co-administered drugs. This study aimed to in- 
vestigate the metabolism of six 4-substituted analogs of methamphetamine (MA), and their potential inhibition of MA 
metabolism. The metabolism of MA and the 4-substituted MAs was examined in vitro using human metabolic enzymes. 
Metabolite analyses were performed using trifluoroacetyl derivatization and GC-MS. The experiments showed that cy- 
tochrome P450 2D6 (CYP2D6) was involved in the major metabolic pathway of MA, where it catalyzed N-demethyla- 
tion of 4-fluoromethamphetamine (4-FMA), 4-chloromethamphetamine (4-CMA), 4-bromomethamphetamine (4-BMA), 
4-iodomethamphetamine (4-IMA) and 4-nitromethamphetamine (4-NMA), and O-demethylation of 4-methoxyme- 
thamphetamine (4-MMA). The half maximal inhibitory concentration (IC50) values for CYP2D6 using MA as substrate 
were different for each of the 4-substituted MAs. The strongest inhibitors of amphetamine production from MA were, in 
order, 4-IMA, 4-BMA, 4-CMA, 4-MMA, 4-FMA, and 4-NMA. The same order was observed for the IC50 values for in- 
hibition of p-hydroxymethamphetamine production from MA, except for the IC50 of 4-MMA. The IC50 values of 4-IMA 
were lower than the IC50 values of fluoxetine and higher than that of quinidine. The results of this study imply that the 
risk of illicit drug interactions fluctuates so widely that unintentional fatal drug poisonings could occur. 
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1. Introduction 
Designer drugs are a serious problem worldwide, espe- 
cially among young people, and in some cases they have 
resulted in fatal poisoning [1-7]. New designer drugs are 
created by changing the molecular structure of an exist- 
ing drug. This creates a compound with similar pharma- 
cological effects, and is performed to circumvent existing 
drug laws. For example, 4-methoxymethamphetamine (4- 
MMA) and 4-fluoromethamphetamine (4-FMA), which 
are 4-substituted psychoactive analogs of methampheta- 
mine (MA), have emerged on the illicit drug market [1,2, 
8-11]. Designer drugs such as illicit amphetamine-type  
stimulants are often co-administered with other drugs in 
tablet, capsule, or powder form [12-17]. The emergence 
of new designer drugs and co-administration of drugs have 
made it difficult to discriminate controlled substances in fo- 
rensic samples, and have increased drug-related problems. 
We previously reported a method for distinguishing 
currently controlled substances, such as MA, 4-MMA, 
and 4-FMA, from other uncontrolled 4-substituted MAs, 
including 4-chloromethamphetamine (4-CMA), 4-bromo- 
methamphetamine (4-BMA), 4-iodomethamphetamine 
(4-IMA), and 4-nitromethamphetamine (4-NMA) [18]. 
As a way to circumvent existing drug laws, production 
and subsequent abuse of 4-CMA, 4-BMA and 4-NMA is 
expected in future because details of their psychotomi-  *Corresponding author. 
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metic properties and synthetic processes are easy to ob- 
tain online [19]. Additionally, like 4-iodo-2, 5-dimetho- 
xy-phenethylamine (2C-I) and 4-iodo-2, 5-dimethoxyam- 
phetamine (DOI), which have been widely abused as 
designer drugs, 4-IMA also has a 4-iodinated aromatic 
part. Therefore, it is expected that these 4-substituted 
analogs of MA will be encountered in forensic cases in 
the future. 
In general, the most common types of metabolic drug- 
drug interactions are inhibition and induction of drug 
metabolizing enzymes. These interactions can increase or 
decrease drug exposure when two or more drugs are 
co-administered, and this can enhance drug toxicity [20]. 
However, there is little information available about the 
ability of designer drugs to inhibit the metabolism of the 
other drugs administered. Evaluation of the potential risk 
of metabolic drug-drug interactions is important. In this 
investigation, in vitro experiments with human metabolic 
enzymes were used to study the major metabolites of six 
4-substituted MAs and their ability to inhibit the metabo- 
lism of MA. 
2. Materials and Methods 
2.1. Chemicals and Reagents 
MA was purchased from Dainippon Pharmaceutical 
(Osaka, Japan), and 4-MMA and p-hydroxymethamphe- 
tamine (OHMA) were obtained from Sigma-Aldrich (St 
Louis, MO). Amphetamine (AP) was donated by the Mi- 
nistry of Health, Labour and Welfare, Japan. 4-Chloro- 
phenylacetone, 4-bromophenylacetone, and sodium cya- 
noborohydride were purchased from Kanto Chemical Co., 
Inc. (Tokyo, Japan). 4-Fluorophenylacetone, 4-nitrophe- 
nylacetone, 4-iodophenylacetic acid, and acetic anhy- 
dride were purchased from Wako Pure Chemical Indus- 
tries Ltd. (Osaka, Japan). Trifluoroacetic anhydride (TFA) 
was obtained from Nacalai Tesque (Kyoto, Japan). Am-
monium acetate was purchased from Katayama Chemical 
Industries Co., Ltd. (Osaka, Japan). All other chemicals 
were purchased from commercial sources and used with- 
out further purification. 
Pooled human liver microsomes (HLM, BD Ultra- 
Pool™ HLM 150), Solution A (31 mmol/L NADP+, 66 
mmol/L glucose-6-phosphate, and 66 mmol/L MgCl2 in 
water) and Solution B (40 U/mL glucose-6-phosphate de- 
hydrogenase in 5 mmol/L sodium citrate buffer) for a 
NADPH regenerating system, and 0.5 mol/L potassium 
phosphate buffer (pH 7.4) were supplied by BD Biosci-
ences (San Jose, CA). Microsomes from baculovirus- 
infected insect cells (expressing CYP1A2, CYP2C9, 
CYP2C19, CYP2D6, CYP3A4 and CYP3A5) were also 
obtained from the BD Biosciences. 
2.2. Synthesis of Standards 
Five 4-substituted analogs of MA and five 4-substituted 
analogs of AP were synthesized. They were obtained by 
reductive amination of 4-substituted phenylacetones in 
methanol with sodium cyanoborohydride [21]. The syn- 
thesized compounds were ascertained by matrix-assisted 
laser desorption/ionization time-of-flight mass spectrome- 
try (MALDI-TOF/MS) or liquid chromatographyelectro- 
spray ionization-time-of-flight mass spectrometry (LC- 
ESI-TOF-MS). 
4-FMA: A mixture of 4-fluorophenylacetone (1 mmol), 
40% methylamine methanol solution (1.5 mmol), acetic 
acid (2 mmol), and sodium cyanoborohydride (1.5 mmol) 
was stirred overnight at room temperature in methanol. 
After the reaction, methanol was evaporated in vacuo and 
2 M hydrochloric acid solution was added to the residue. 
The aqueous solution was stirred for 0.5 h at room tem- 
perature, after which 1 M aqueous sodium hydroxide was 
added to make the solution alkaline. The aqueous layer 
was extracted with dichloromethane, and the combined 
organic layer was washed with brine, dried over anhy- 
drous sodium sulfate, and concentrated. Ethereal hydro- 
chloric acid was added to the residue. The solution was 
allowed to stand at 5˚C until precipitation occurred. The 
precipitate was then filtered off, and the residue was 
washed with pre-chilled diethyl ether and air dried to 
afford 4-FMA hydrochloride. The protonated molecular 
ion of 4-FMA, [MH]+, was observed at m/z 168.224 by 
MALDI-TOF/MS. 
4-CMA: The same procedure as that for 4-FMA hy- 
drochloride was carried out for 4-chlorophenylacetone (1 
mmol), which was used as the starting material to obtain 
4-CMA hydrochloride. The protonated molecular ion of 
4-CMA, [MH]+, was observed at m/z 184.156/186.122 by 
MALDI-TOF/MS. 
4-BMA: The same procedure as that for 4-FMA hy- 
drochloride was carried out for 4-bromophenylacetone (1 
mmol), which was used as the starting material to obtain 
4-BMA hydrochloride. The protonated molecular ion of 
4-BMA, [MH]+, was observed at m/z 228.115/230.085 by 
MALDI-TOF/MS. 
4-IMA: 4-iodophenylacetone was prepared by reflu- 
xing 4-iodophenylacetic acid (2 mmol) and acetic anhy- 
dride with pyridine [22]. The same procedure as that for 
4-FMA hydrochloride was performed for 4-iodopheny- 
lacetone, which was used as the starting material to ob- 
tain 4-IMA hydrochloride. The protonated molecular ion 
of 4-IMA, [MH]+, was observed at m/z 276.130 by 
MALDI-TOF/MS. 
4-NMA: The same procedure as that for 4-FMA hy- 
drochloride was carried out for 4-nitrophenylacetone (1 
mmol), which was used as the starting material to obtain 
4-NMA hydrochloride. The protonated molecular ion of 
4-NMA, [MH]+, was observed at m/z 195.059 by  
MALDI-TOF/MS. 
Five 4-substituted analogs of AP, 4-Fluoroampheta- 
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mine (4-FAP), 4-Chloroamphetamine (4-CAP), 4-Bromo- 
amphetamine (4-BAP), 4-Iodoamphetamine (4-IAP) and 
4-Nitroamphetamine (4-NAP), were synthesized by the 
same procedures as above reported 4-substitued MAs, 
but using ammonium acetate instead of methylamine. The 
protonated molecular ion [MH]+ of 4-FAP, 4-CAP, 4- 
BAP, 4-IAP and 4-NAP were observed at m/z 154.10, 
m/z 170.07/172.07, m/z 214.02/216.02, m/z 262.01 and 
m/z 181.10 by LC-ESI-TOF-MS, respectively. 
2.3. Microsomal Incubation and Workup for  
Metabolism Experiments 
Incubation mixtures (final volume: 100 μL for HLM, 200 
μL for CYP1A2, CYP2C9, CYP2C19, CYP2D6,  
CYP3A4, and CYP3A5) consisted of 0.1 mol/L potassi- 
um phosphate buffer (pH 7.4), 1.55 mmol/L NADP+, 3.3 
mmol/L glucose 6-phosphate, 3.3 mmol/L MgCl2 and 0.4 
U/mL glucose-6-phosphate dehydrogenase, and the sub- 
strate. The substrate was either MA (final concentration: 
2, 5, 10, 20, 50, 100, 200, 500, 1000 or 1500 μmol/L in 
water) or a 4-substituted MA (4-FMA, 4-CMA, 4-BMA, 
4-IMA, 4-NMA, 4-MMA; final concentration 1 mmol/L 
in water). The mixtures were incubated at 37˚C. Reac- 
tions were started by adding ice-cold microsomes (final 
concentration: 2 mg/mL for HLM, 40 pmol/mL for 
CYP1A2, CYP2C19, and CYP2D6, 80 pmol/mL for 
CYP2C9, CYP3A4, and CYP3A5) and terminated with 
200 μL of methanol after 30 min of incubation. After 
termination, the samples were placed on wet ice and 
centrifuged. The supernatants were transferred to clean 
test tubes, and 600 mL of carbonate-bicarbonate buffer 
(pH 9.8) and 100 μL of 0.92 μmol/L N-butylbenzyla- 
mine methanolic (internal standard) were added. Each su- 
pernatant was extracted three times with 1 mL of 2-pro- 
panol-chloroform (1:3; v/v). The combined organic layer 
was transferred into a glass flask and 200 μL of 0.24 
mol/L methanolic HCl was added, and the sample was 
evaporated to dryness under a stream of nitrogen. The 
residue was subjected to TFA-derivatization (Section 2.5), 
and then dissolved in 100 or 1000 μL of ethyl acetate. An 
aliquot (1 μL) of the derivatized sample was injected into 
the gas chromatography-mass spectrometry (GC-MS) sys- 
tem. 
2.4. Microsomal Incubations for Inhibition  
Studies 
Mixtures (final volume: 200 mL, n = 3) containing 0.1 
mol/L potassium phosphate buffer (pH 7.4), 1.55 mmol/L 
NADP+, 3.3 mmol/L glucose 6-phosphate, 3.3 mmol/L 
MgCl2, 0.4 U/mL glucose-6-phosphate dehydrogenase, 
and substrate MA (final concentration: 20 mmol/L) were 
incubated in the presence or absence of a potential in- 
hibitor (4-FMA, 4-CMA, 4-BMA, 4-IMA, 4-NMA or 
4-MMA). The final concentration of the inhibitor was 0.3, 
1, 3, 10 or 30 μmol/L. Alternatively, the mixture was in- 
cubated with a well-known inhibitor (fluoxetine or qui- 
nidine) with a final inhibitor concentration of 0.3, 1, 3, 
10 or 30 μmol/L for fluoxetine and 0.3, 1, 3, 10 or 30 
nmol/L for quinidine. The mixtures were incubated at 
37˚C for 30 min. The methanol volume fraction was 
below 0.3% in all samples. Reactions were started by 
adding ice-cold microsomes containing CYP2D6 (final 
concentration: 40 pmol/mL) and terminated with 200 μL 
of methanol. After termination, the sample workup was 
as described in Section 2.3, and the samples were ana- 
lyzed by GC-MS. 
2.5. GC-MS 
GC-MS analysis of MA, AP, OHMA and the six 4-sub- 
stituted MAs and 4-substituted APs was performed as 
follows. A Shimadzu 17-A gas chromatograph equipped 
with a QP-5050A mass spectrometer (Kyoto, Japan) was 
operated under the following conditions: ionization mode, 
electron ionization; ionization energy, 70 eV; carrier gas, 
helium; flow rate, 1.9 mL/min; capillary column, DB5- 
MS (Agilent, Santa Clara, CA, 30 m × 0.25 mm i.d., 0.25 
μm film thickness); injector temperature, 200˚C; injec- 
tion mode, splitless; and scan range, m/z 35 - 375. The 
oven temperature was held at 60˚C for 2 min, then in- 
creased to 250˚C at 20˚C/min and held for 3 min. 
TFA derivatives of the analytes were prepared by ad- 
ding 100 μL of TFA and 100 μL of ethyl acetate to the 
sample, after which the mixture was reacted at 65˚C for 
10 min. The reaction mixture was carefully evaporated 
and dried under a gentle nitrogen stream, and then recon- 
stituted in 100 or 1000 μL of ethyl acetate. Subsequently, 
1 μL aliquots were automatically injected into the GC- 
MS system within 3 h of reconstitution [23].  
For quantification, the following target ions (m/z) were 
used in selected ion monitoring mode: m/z 118 for AP, 
m/z 154 for OHMA, and m/z 91 for the internal standard 
(IS) N-butylbenzylamine. Calibration curves for AP and 
OHMA were constructed based on the ion peak-area ra- 
tio of internal standard to AP or OHMA from 100 μL 
(final concentration of 0.01, 0.2, 0.4, 0.6, 0.8 or 1 μmol/L) 
or 1000 μL (final concentration of 0.6, 4, 8 or 12 μmol/L) 
samples. Good linearity was confirmed for all data. 
To examine the impact of the in vitro incubation ma- 
trix, inactivated incubation mixtures spiked with blank 
water or known concentrations (sample volume of 100 
μL, final concentration of 0.01, 0.1 or 1 μmol/L in water; 
sample volume of 1000 μL, final concentration of 0.1, 1 
or 10 μmol/L in water) of a mixture of AP and OHMA 
were extracted as described in Section 2.3. The obtained 
calibration curves were virtually the same as those for 
quantification. The analysis results for inactivated incu- 
bation mixtures spiked with the mixture of AP and 
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of 2, 5, 10, 20, 50, 100, 200, 500, 1000 or 1500 μmol/L 
was used for the kinetic study. Kinetic data were ana- 
lyzed by the Michaelis-Menten equation (v = Vmax[S]/ 
(Km + [S])) and Hanes-Woolf equations ([S]/v = 
1/Vmax[S] + Km/Vmax), where v is the initial reaction ve- 
locity, Vmax the maximal reaction velocity, Km the 
Michaelis constant, and [S] is the substrate concentra- 
tion. IC50 values were calculated according to the fol- 
lowing Equation (1): 
OHMA showed there was no interference from the in 
vitro incubation matrix (Table 1 and Figure 1). 
2.6. Kinetics 
The effects of the CYP2D6 protein content and incuba- 
tion time were evaluated to obtain the optimum condi- 
tions for linearity of the metabolic results. The resulting 
conditions for the kinetics study were a 40 pmol/mL 
protein concentration in the microsomes and a 30 min 
incubation at 37˚C. Substrate MA at a final concentration  
     [log / 50 / log ]
50IC 10
A B C D C B             (1) 
 
Table 1. Validation data for quantitative analysis of the incubation matrix spiked with AP and OHMA by GC-MS after de- 
termination of TFA derivatization. The results are based on mass chromatograms (SIM mode) obtained with a sample vol- 
ume of 100 mL or 1000 mL. 
Intraday CV(%)a Interday CV(%)a Sample volume 
for GC/MS  
analysis 
Compound Correlation coefficient  mol/L 0.1 mol/L 1 mol/L  mol/L 0.1 mol/L 1 mol/L 
APb 0.9999 3.1 5.9 0.9 3.3 2.6 8.2 
100 L 
OHMAc 0.9993 17.9 9.9 15.4 10.4 14.8 25.1 
    mol/L  mol/L 10 mol/L  mol/L 1 mol/L 10 mol/L
APb 0.9999 12.1 2.3 2.7 7.5 6.1 2.6 
1000 L 
OHMAc 0.9991 20.3 8.1 4.6 4.8 9.2 5.6 
aEach value was obtained from three determinations, bThe peak area of the base peak ion at m/z 118 was used, cThe peak area of the base peak ion at m/z 154 
was used. 
 
 
(a)                                          (b) 
Figure 1. The mass chromatogram (SIM mode) of blank incubation matrix extract (a) and incubation matrix spiked with 
each analyte (final concentration of 0.01 mol/L) and the IS (b). 
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where A and B are the higher and lower concentrations 
near 50% inhibition, respectively; and C and D are the 
percentages of control B and A, respectively. 
3. Results and Discussion 
3.1. In Vitro Metabolism of MA and  
4-Substituted MAs 
MA was incubated with recombinant CYP1A2, CYP2C9, 
CYP2C19, CYP2D6, CYP3A4, CYP3A5 and HLM, and 
the main metabolites of MA, AP and OHMA, were for- 
med (Figure 2). The production rates of the metabolites 
differed greatly depending on the enzyme (Table 2). 
With all of the enzymes tested, AP production from MA 
was greater than OHMA production. Therefore, N-deme- 
thylation of MA was superior to p-hydroxylation with 
these enzymes. Among the CYP isozymes tested, CYP2D6 
was the dominant contributor to MA metabolism. Similar 
findings were reported by Kuwayama et al. and Lin et al., 
who found that CYP2D6 was the main enzyme that me- 
tabolized 3,4-methylenedioxymethamphetamine (MDMA) 
[24,25]. 
4-FMA, 4-CMA, 4-BMA, 4-IMA, 4-NMA, and 4- 
MMA were incubated independently with CYP2D6. Me- 
tabolites from N-demethylation of 4-FMA, 4-CMA, 4- 
BMA, 4-IMA and 4-NMA, and from O-demethylation of 
4-MMA were detected (Figures 3 and 4). The results 
suggest that when any of these six 4-substituted MAs are 
taken, these metabolites will be present in human body 
fluids and tissues obtained from the user. This study us- 
ing CYP2D6 and HLM showed that 4-MMA was me- 
tabolized mainly by O-demethylation, which agrees with 
the results of Staack et al. [8]. 
The production rates of the main metabolites of MA, 
AP and OHMA, were measured at various MA concen- 
trations using microsomes from cells that stably express 
human CYP2D6, which was the dominant contributor to 
the metabolism of MA. The curves for the two main me- 
tabolites were fitted to the Michaelis-Menten equation 
(Figure 5). The Km values for MA N-demethylation 
(Figure 5(a)) and p-hydroxylation (Figure 5(b)) were 
estimated to be 30 and 70 μmol/L, respectively. The Vmax 
values for MA N-demethylation and p-hydroxylation were 
5.8 and 0.45 pmol/(min × pmol), respectively. 
3.2. Comparison of Inhibitory Activity of the Six  
4-Substituted MAs toward CYP2D6- 
Mediated Metabolism of MA 
To determine the IC50 values for CYP2D6, the percent- 
age values of AP and OHMA production activity were 
plotted against the concentrations for each inhibitor (Fig- 
ures 6 and 7). The percentage production activities were 
calculated by comparison with production activities for 
P and OHMA production without inhibitor. The results A 
 
Figure 2. Metabolism of methamphetamine (MA) to am- 
phetamine (AP) and p-hydroxymethamphetamine (OHMA). 
 
 
Figure 3. Metabolism of 4-substituted methamphetamines 
(4-MAs) and 4-methoxymethamphetamine (4-MMA) to sub- 
stituted amphetamines (4-APs) and p-hydroxymethamphe- 
tamine (OHMA), respectively. 
 
Table 2. Metabolism of methamphetamine (1 mmol/L) with 
various enzymes. 
Production Rate of Metabolite  
[pmol/(min × pmol P450)]a Metabolic Enzyme
AP OHMA 
CYP1A2 0.62 ± 0.05 0.028 ± 0.006 
CYP2C9 0.15 ± 0.05 0.022 ± 0.006 
CYP2C19 0.86 ± 0.13 0.27 ± 0.05 
CYP2D6 5.8 ± 0.9 0.48 ± 0.13 
CYP3A4 0.11 ± 0.01 0.043 ± 0.01 
CYP3A5 0.089 ± 0.024 0.027 ± 0.009 
HLM 0.14 ± 0.02 0.018 ± 0.003 
aEach value represents the mean ± SD from three independent experiments. 
 
showed that the IC50 values against AP production from 
MA decreased in the following order: quinidine > 4-IMA 
> fluoxetine > 4-BMA > 4-CMA > 4-MMA > 4-FMA > 
4-NMA. The same trend was observed for the IC50 values 
against OHMA production from MA, except for the IC50 
of 4-MMA. In the profile for inhibition of CYP2D6 by 
4-MMA, OHMA production from MA increased at a rate 
almost proportional to the amount of 4-MMA added. 
Therefore, the effect of 4-MMA on OHMA formation 
from MA with CYP2D6 was not included in further 
analysis of the trend. The profile for inhibition of  
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Figure 4. EI mass spectra and retention indices (RI) of trifluoroacetic acid (TFA) derivatized 4-substituted analogs of am-
phetamine (AP) produced by synthesis or from metabolism of the corresponding substituted MA with CYP2D6. 
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(a)                                        (b) 
Figure 5. Michaelis-Menten plot for N-demethylation (a) and p-hydroxylation (b) of methamphetamine (MA) by recombinant 
CYP2D6. Vmax and Km values were calculated from the Hanes—Woolf approximation of the Michaelis—Menten theory. The 
curves were fitted by nonlinear regression according to the Michaelis—Menten equation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Inhibition of CYP2D6-mediated N-demethylation by 4-fluoromethamphetamine (4-FMA), 4-chloromethampheta- 
mine (4-CMA), 4-bromomethamphetamine (4-BMA), 4-iodomethamphetamine (4-IMA), 4-nitromethamphetamine (4-NMA), 
4-methoxymethamphetamine (4-MMA), fluoxetine and quinidine in human liver microsomes using methamphetamine (MA) 
as a substrate. The substrate concentration was lower than the Km (see Figure 5). Data points represent the average of three 
determinations per concentration and error bars represent standard deviations. 
 
CYP2D6 by 4-MMA suggested that the production rate 
of OHMA from 4-MMA was much faster than the pro- 
duction rate of OHMA from MA. 
The general trend was that the strength of inhibition of 
CYP2D6-mediated N-demethylation and p-hydroxylation 
increased as the halogen group of the 4-halogenated MA 
became larger. This structure-activity relationship is inte- 
resting because of its relevance to the 2Cx and DOx 
families of drugs, which have been widely abused. These 
drug families include 2C-I and DOI, which are 4-halo-  
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Figure 7. Inhibition of CYP2D6-mediated p-hydroxylation by 4-fluoromethamphetamine (4-FMA), 4-chloromethampheta- 
mine (4-CMA), 4-bromomethamphetamine (4-BMA), 4-iodomethamphetamine (4-IMA), 4-nitromethamphetamine (4-NMA), 
4-methoxymethamphetamine (4-MMA), fluoxetine and quinidine in human liver microsomes using methamphetamine (MA) 
as a substrate. Concentration scales of the inhibitors are logarithmic except for 4-MMA. The substrate concentration was 
lower than the Km (see Figure 5). Data points represent the average of three determinations per concentration and error bars 
represent standard deviations. 
 
genated aromatic compounds like those studied here. 
Comparison of the IC50 values of the compounds in 
this study, suggested that the strength of drug interactions 
could alter greatly with a change in the substituent. There- 
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fore, designer drugs could interact with other drugs in an 
unexpected manner, and carry unknown risks and unfore- 
seen consequences. 
4. Conclusion 
This study investigated the in vitro metabolism of six 4- 
substituted MAs and their potential inhibition of MA me- 
tabolism using human metabolic enzymes by GC-MS 
after TFA derivatization. MA was mainly metabolized by 
CYP2D6, which catalyzed N-demethylation of 4-FMA, 
4-CMA, 4-BMA, 4-IMA and 4-NMA, and catalyzed O- 
demethylation of 4-MMA. The IC50 values for the 4- 
substituted MAs for CYP2D6-catalyzed AP and OHMA 
production from MA were, in descending order, 4-IMA > 
4-BMA > 4-CMA > 4-MMA > 4-FMA > 4-NMA. The 
IC50 of 4-MMA against OHMA production was the only 
exception to this trend. The IC50 values were between 
0.80 and >30 μmol/L for AP production and 0.84 and 
>30 μmol/L for OHMA production. These results show 
that although amphetamine-type stimulants with similar 
chemical structures can be metabolized by the same me- 
tabolic enzymes, they interact with co-administered com- 
pounds to varying degrees. This suggests that the risk of 
illicit drug interactions fluctuates so widely that drug abu- 
sers could not be aware of the potential danger of these 
interactions. 
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